EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Peripheral blood CD8 + T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients

Fang Chen, Ping Liu, Jiajia Zhao, Demin Wang, Haifeng Zhen, Juan Jin, Zhi Chao, Dan Zhou, Lu Zhang, Wei Chen, Zimian Luo, Zhongjun Huo

Annals of Hematology · 15.07.2026 · 105 (11)

DOI: 10.1007/s00277-026-07135-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 15.07.2026. Verfasst von Fang Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Central Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse, CD8-Positive T-Lymphocytes. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Research Topics of Hunan Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While the prognostic significance of peripheral blood (PB) lymphocyte counts in diffuse large B-cell lymphoma (DLBCL) patients treated with Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Prednisone (R-CHOP) is established, the specific role of CD8+ T-cell counts (CD8c) remains unclear. Methods: This retrospective study analyzed 315 newly diagnosed DLBCL patients treated at Central Hospital of Xiangtan from January 2018 to September 2023. We evaluated the prognostic significance of initial CD8c and other clinical parameters using univariate and multivariate survival analyses to identify independent predictors of outcome. An optimal CD8c cut-off value of 264.5×106/L was identified. Low CD8c correlated with significantly improved 5-year progression-free survival (PFS) (88.78% vs 49.18%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseCD8-Positive T-LymphocytesHumansVincristinePrednisoneDoxorubicinRituximabFemaleCyclophosphamideRetrospective StudiesMaleMiddle AgedPrognosisAgedAdultLymphocyte CountAged, 80 and overYoung Adult

Stichwörter der Autor:innen

CD8 + T-cell countDiffuse large B-cell lymphomaPrognostic factorR-CHOP therapySurvival analysis

Substanzen

VincristinePrednisoneDoxorubicinRituximabCyclophosphamideR-CHOP protocol

Autor:innen und Institutionen

  • Central Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
  • Lu'an Maternal and Child Health Hospital, Lu'an, 237006, China.
  • Central Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China. 1840059465@qq.com.
  • Central Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China. huozj0102@163.com.

Förderung

  • Health Research Topics of Hunan Provincial Health Commission

Zitieren

APA

Chen, F., Liu, P., Zhao, J., Wang, D., Zhen, H., Jin, J., Chao, Z., Zhou, D., Zhang, L., Chen, W., Luo, Z., & Huo, Z. (2026). Peripheral blood CD8 + T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07135-5

Vancouver

Chen F, Liu P, Zhao J, Wang D, Zhen H, Jin J, et al. Peripheral blood CD8 + T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07135-5

BibTeX
@article{Chen2026,
  author = {Chen, Fang and Liu, Ping and Zhao, Jiajia and Wang, Demin and Zhen, Haifeng and Jin, Juan and Chao, Zhi and Zhou, Dan and Zhang, Lu and Chen, Wei and Luo, Zimian and Huo, Zhongjun},
  title = {Peripheral blood CD8 + T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07135-5}
}
Kostenlos starten →